![]() |
市場調查報告書
商品編碼
1486840
輸液治療設備的全球市場 - 市場分析、競爭格局、市場預測(2030 年)Infusion Therapy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
到2030年,全球輸液治療設備市場規模預計將達到776.5億美元,2024-2030年預測期間複合年增長率為6.56%。輸液治療設備的需求激增主要是由於糖尿病和癌症等慢性病盛行率的上升所推動的。輸液治療設備涵蓋了廣泛的臨床治療領域,市場呈現顯著成長,產品投放數量顯著增加。這些因素共同促進了輸液治療設備市場在 2024-2030 年預測期內的成長軌跡。
輸液治療設備市場動態
世界各地的糖尿病和癌症流行正在推動輸液治療設備市場的顯著成長。根據國際糖尿病聯盟(IDF)估計,到 2021 年,預計將有 5.37 億 20 歲至 79 歲之間的成年人患有糖尿病。預計到 2030 年,這一數字將增至 6.43 億,到 2045 年將增至 7.83 億。此外,據報導有 5.41 億人存在糖耐受性受損 (IGT),這使他們患 2 型糖尿病的風險增加。值得注意的是,四分之三的成人糖尿病患者生活在低收入和中等收入國家,這些國家對胰島素幫浦等先進醫療設備的需求非常高。這些醫療設備對於持續、準確地施用胰島素至關重要,對於有效的血糖管理也至關重要。
美國癌症協會發佈的癌症統計數據也推動了對輸液治療設備的需求。 2020年,預計全球將出現1,930萬新發癌症病例,其中不包括1,810萬例非黑色素瘤皮膚癌。乳癌佔新發病例的 11.7%,超過肺癌(11.4%),使其成為最常診斷的癌症。在其他癌症中,最常見的是大腸直腸癌(10.0%)、攝護腺癌(7.3%)和胃癌(5.6%)。輸液治療對於化療至關重要,進一步強調了這些設備在癌症治療中的重要作用。
輸液治療設備市場也受惠於產業公司之間不斷增加的聯盟和合作關係。例如,2023年8月,芬蘭醫療技術公司Monidor Oy與國際領先醫療設備製造商貝朗公司合作,加強遠距輸液治療監測。像這樣的合作關係對於推進輸液治療領域至關重要。
另一個重大進展是,Eitan Medical 於 2021 年 4 月宣佈推出革命性的互聯多療法門診輸液系統 Avoset。憑藉其緊湊的設計和遠端監控功能,Avoset 旨在改變急性後護理和專業輸液治療,提高患者安全和使用者體驗。
儘管存在這些積極趨勢,但市場仍面臨課題,例如輸液治療設備的高成本以及與其使用相關的感染風險。這些因素可能會限制 2024-2030 年預測期間的市場成長。然而,由於有效管理糖尿病和癌症等慢性病的需求不斷增長,預計輸液治療設備市場的整體擴張將持續。
輸液治療設備市場區隔分析
注射器輸液幫浦預計將在 2023 年佔據輸液治療設備市場的主要收入佔有率。注射器輸液幫浦(注射器驅動器)以其精確性而聞名,對於將少量液體(例如藥物和營養物質)直接注入患者的血液中至關重要。
注射器輸液幫浦具有多重優點,使其在臨床實務中不可或缺。這些設備用途廣泛,專為便攜式和固定用途而設計,並包括用於溫度控制的內部加熱器。此功能對於注射需要特定溫度設定以保持有效性的輸注液特別有益。此外,注射幫浦可以與電腦交互,允許醫療保健提供者對設備進行編程,以提高準確性並追蹤輸液歷史,從而最大限度地減少出錯的可能性。
本報告研究和分析了全球輸液治療設備市場,提供市場規模和預測、驅動因素和課題、公司和產品概況等。
Infusion Therapy Devices Market By Product Type (Syringe Infusion Pumps, Large Volume Pumps, Elastomeric Pumps, And Others), Mobility (Portable Infusion Pumps, And Stationary Infusion Pumps), Application (Multiple Sclerosis, Diabetes, Rheumatoid Arthritis, Cancer, And Others), End-User (Hospitals And Clinics, Ambulatory Surgical Centers, Homecare And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady cagr forecast till 2030 owing to rise in the prevalence of chronic disorders and increasing clinical applications of infusion therapy devices
The global Infusion Therapy Devices market is estimated to grow at a CAGR of 6.56% during the forecast period from 2024 to 2030 to reach USD 77.65 billion by 2030. The surge in demand for Infusion Therapy Devices is predominantly driven by critical factors such as the escalating prevalence of chronic disorders like diabetes and cancer. With infusion therapy devices encompassing a broad spectrum of clinical treatments, coupled with a notable increase in product launches, the market is experiencing a significant upswing. These factors collectively contribute to fostering a positive trajectory for the growth of the infusion therapy devices market throughout the forecast period spanning from 2024 to 2030.
Infusion Therapy Devices Market Dynamics:
The global prevalence of diabetes and cancer is driving significant growth in the market for infusion therapy devices. According to the International Diabetes Federation (IDF), in 2021, an estimated 537 million adults aged 20-79 were living with diabetes. This number is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, 541 million individuals were reported to have Impaired Glucose Tolerance (IGT), putting them at high risk of developing Type 2 diabetes. Notably, three-quarters of adults with diabetes reside in low- and middle-income countries, where the need for advanced medical devices like insulin pumps is crucial. These devices are essential for continuous and precise insulin delivery, and vital for effective blood sugar management.
The demand for infusion therapy devices is also bolstered by the cancer statistics published by the American Cancer Society. In 2020, there were an estimated 19.3 million new cancer cases worldwide, excluding 18.1 million cases of non-melanoma skin cancer. Breast cancer has emerged as the most commonly diagnosed cancer, comprising 11.7% of new cases, surpassing lung cancer, which accounts for 11.4% of cases. The other prevalent cancers include colorectal (10.0%), prostate (7.3%), and stomach (5.6%). Infusion therapy is integral to chemotherapy delivery, further underscoring the critical role of these devices in cancer treatment.
The infusion therapy devices market is also benefiting from increased collaborations and partnerships among industry players. For instance, in August 2023, Monidor Oy, a Finnish health technology company, partnered with B. Braun, a leading international medical device manufacturer, to enhance remote IV therapy monitoring. Such partnerships are pivotal in advancing the field of infusion therapy.
In another significant development, Eitan Medical introduced a groundbreaking connected multi-therapy ambulatory infusion system, Avoset, in April 2021. Avoset is designed to transform post-acute care and specialized infusion therapy with its compact design and remote monitoring capabilities, enhancing patient safety and user experience.
Despite these positive trends, the market faces challenges such as the high cost of infusion therapy devices and the risk of infection associated with their use. These factors may restrain market growth during the forecast period of 2024 to 2030. However, the overall expansion of the infusion therapy device market is expected to continue, propelled by the rising need to manage chronic diseases like diabetes and cancer effectively.
Infusion Therapy Devices Market Segment Analysis:
Infusion Therapy Devices Market by Product Type (Syringe Pumps, Large Volume Pumps (LVP), Elastomeric Pumps, and Others), Mobility (Portable Infusion Pumps, and Stationary Pumps), Application (Multiple Sclerosis, Diabetes, Rheumatoid Arthritis, Cancer, and Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
The syringe infusion pump segment is poised to capture a substantial revenue share of the infusion therapy devices market in 2023. Known for their precision, syringe infusion pumps, or syringe drivers, are crucial for administering small volumes of fluids, such as medications or nutrients, directly into a patient's bloodstream.
Syringe infusion pumps offer several advantages, making them indispensable in clinical settings. These devices are versatile, designed for both portable and stationary use, and incorporate an internal heater for temperature control. This feature is particularly beneficial for administering fluids that require specific temperature settings to maintain efficacy. Furthermore, syringe pumps can interface with computers, allowing healthcare providers to program the device for enhanced accuracy and to track the history of infusions, minimizing the potential for errors.
The capability to deliver fluids with higher viscosity is another notable benefit. These pumps can operate continuously for up to 24 hours, ensuring that patients receive a consistent and precise dosage of medication over a specified period. They also allow for the mixing and administering of multiple medications simultaneously, significantly reducing the need for frequent injections and improving patient comfort.
The demand for syringe infusion pumps is expected to grow due to their ability to deliver an accurate dosage over extended periods, which is increasingly essential in both acute and chronic care settings. This growth is further supported by the introduction of new and innovative products that have received regulatory approvals. For example, in August 2021, Baxter's Novum IQ syringe infusion pump received FDA 510(k) clearance. This device enhances the infusion process with advanced safety features, improved connectivity, configurable anesthesia care settings, and a user-friendly interface, emphasizing precision and reliability in medication delivery.
Given these developments, the syringe infusion pump segment is anticipated to experience notable growth, significantly contributing to the expansion of the overall infusion therapy device market from 2024 to 2030.
North America Is Expected To Dominate The Overall Infusion Therapy Devices Market:
North America is projected to dominate the Infusion Therapy Devices market in 2023, buoyed by its advanced healthcare infrastructure and a high incidence of chronic diseases such as diabetes, cancer, and arthritis. The region's robust growth is further supported by continual technological advancements, the presence of major industry players, and a dynamic market environment conducive to product development and launches.
According to 2023 data from the Centers for Disease Control and Prevention (CDC), approximately 53.2 million people, or one in five U.S. adults, had doctor-diagnosed arthritis between 2019 and 2021. Arthritis is more prevalent among women (20.9%) than men (16.3%), and the likelihood of developing the condition increases with age. Notably, the prevalence of arthritis is higher among those with no leisure-time physical activity (30.9%) compared to those who are somewhat active (27.0%) or meet physical activity recommendations (18.8%). For individuals with arthritis where oral medications are ineffective, infusion therapy serves as a vital alternative, offering direct and rapid delivery of medication into the bloodstream.
The market is also stimulated by the strategic activities of leading companies based in the region, such as Mindray, Baxter, and Becton, Dickinson and Company. These firms play a critical role in the sector's growth through continuous innovation and new product offerings. For instance, in February 2023, Mindray launched its BeneFusion i and u Series infusion systems, which are notable for their high precision and user-friendly design. Featuring an intuitive full touch screen and a flat design that highlights essential parameters, the BeneFusion series enhances visibility and usability for medical staff, allowing for safer and more precise operations.
The convergence of these factors, along with ongoing product launches and regulatory approvals, underscores the significant role North America will continue to play in driving the growth of the global Infusion Therapy Devices market from 2024 to 2030.
Infusion Therapy Devices Market Key Players:
Some of the key market players operating in the Infusion Therapy Devices Market include Fresenius Kabi AG, Ossila, Ace-medical, ICU Medical, Chmyx Inc., Mindray, Baxter, Becton, Dickinson and Company, Micrel Medical Devices SA, AKAS Infusions, Narang Medical Limited, Monidor Oy., Smiths Group plc., B. Braun SE, Trivitron Healthcare, Eitan Medical, and Others.
Recent Developmental Activities In The Infusion Therapy Devices Market:
Key Takeaways From The Infusion Therapy Devices Market Report Study
Target Audience Who Can Be Benefited From This Infusion Therapy Device Market Report Study
Frequently Asked Questions For The Infusion Therapy Devices Market
An infusion pump is a medical device utilized to administer fluids, including nutrients and medications, into a patient's body with precise control over the dosage. Widely employed across various clinical environments such as hospitals, nursing homes, and home care settings, these devices play a crucial role in medical treatment.
The global Infusion Therapy Devices market is estimated to grow at a CAGR of 6.56% during the forecast period from 2024 to 2030 to reach USD 77.65 billion by 2030.
The surge in demand for Infusion Therapy Devices is predominantly driven by critical factors such as the escalating prevalence of chronic disorders like diabetes and cancer. With infusion therapy devices encompassing a broad spectrum of clinical treatments, coupled with a notable increase in product launches, the market is experiencing a significant upswing. These factors collectively contribute to fostering a positive trajectory for the growth of the infusion therapy device market throughout the forecast period spanning from 2024 to 2030.
Some of the key market players operating in the Infusion Therapy Devices market include Fresenius Kabi AG, Ossila, Ace-medical, ICU Medical, Chmyx Inc., Mindray, Baxter, Becton, Dickinson and Company, Micrel Medical Devices SA, AKAS Infusions, Narang Medical Limited, Monidor Oy., Smiths Group plc., B. Braun SE, Trivitron Healthcare, Eitan Medical, and others.
North America is projected to dominate the Infusion Therapy Devices market in 2023, buoyed by its advanced healthcare infrastructure and a high incidence of chronic diseases such as diabetes, cancer, and arthritis. The region's robust growth is further supported by continual technological advancements, the presence of major industry players, and a dynamic market environment conducive to product development and launches.